4MN.F · Minerva Neurosciences, Inc

-

Please sign in to comment on 4MN.F

1 Comment

Admin

4 years, 1 month ago

Minerva Neurosciences, Inc is currently in a long term downtrend where the price is trading 11.8% below its 200 day moving average.

From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.8.

Minerva Neurosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 75.5% to $-7M since the same quarter in the previous year.

Finally, its free cash flow grew by 49.5% to $-7M since the same quarter in the previous year.

Based on the above factors, Minerva Neurosciences, Inc gets an overall score of 3/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR
ISIN	US6033801068

Market Cap	2M
PE Ratio	None
Target Price	None
Dividend Yield	0.0%
Beta	1.14

ABOUT

Minerva Neurosciences, Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

4MN.F · Minerva Neurosciences, Inc

-

Minerva Neurosciences, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Minerva Neurosciences, Inc using a moving average strategy